Managing Comorbidities in Psoriasis: A Comprehensive Approach

October 3, 2025

Guselkumab Scores U.S. FDA Nod for Kids With Psoriasis and PsA

September 29, 2025

Access Update: BMS Offers Deep Discounts on Deucravacitinib (Sotyktu)

September 28, 2025

Access Update: Cigna Removes Prior Restrictions for Home Phototherapy

September 3, 2025

Diagnosing GPP Early: Here’s What to Know and Do

August 12, 2025

Catching Immune Drift: A Guide for Dermatology APPs

July 30, 2025

DERM2025 News: J & J’s Icotrokinra Performs Well in High-impact PsO Sites

July 24, 2025

News Your Patients Can Use: U.S. FDA Gives Its Nod to Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body

May 22, 2025

“Advancing Patient-centered Care” in GPP: Spesolimab (Spevigo, Boehringer Ingelheim) Improves Physical Symptoms, QofL

March 9, 2025

Deucravacitinib’s Safety and Efficacy Holds in Five-Year PsO Study

February 25, 2025

Expert Guidance on the Use of Deucravacitinib (Sotyktu, BMS) in PsO

February 11, 2025

News Your PsO Patients Can Use: Guselkumab Shows Significant Skin Clearance in Special Sites

February 6, 2025